

GENENCOR INTERNATIONAL INC

Form 10-Q

August 06, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

(Mark
One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**
For the quarterly period ended June 30, 2004

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**
For the transition period from _____ to _____

Commission file number 000-31167

Genencor International, Inc.

(Exact name of registrant as specified in its charter)

Delaware	16-1362385
(State or other jurisdiction	(I.R.S. Employer
of	Identification Number)
incorporation or	
organization)	

**925 Page Mill Road
Palo Alto, California 94304
(650) 846-7500**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive
offices)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days

Yes ☒ No ☐

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes ☒ No ☐

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Number of Shares Outstanding at July 30, 2004
Common stock, par value \$0.01 per share	59,464,245

TABLE OF CONTENTS

	<u>Page</u>
<u>PART I. FINANCIAL INFORMATION</u>	
<u>Item 1. Financial Statements:</u>	
<u>Condensed Consolidated Unaudited Balance Sheets as of June 30, 2004 and December 31, 2003</u>	4
<u>Condensed Consolidated Unaudited Statements of Operations for the three and six months ended June 30, 2004 and 2003</u>	5
<u>Condensed Consolidated Unaudited Statements of Cash Flows for the six months ended June 30, 2004 and 2003</u>	6
<u>Notes to Condensed Consolidated Unaudited Financial Statements</u>	7
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	13
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	26
<u>Item 4. Controls and Procedures</u>	26
<u>PART II. OTHER INFORMATION</u>	
<u>Item 1. Legal Proceedings</u>	27
<u>Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities</u>	27
<u>Item 3. Defaults Upon Senior Securities</u>	27
<u>Item 4. Submission of Matters to a Vote of Security Holders</u>	28
<u>Item 5. Other Information</u>	28
<u>Item 6. Exhibits and Reports on Form 8-K</u>	29
<u>SIGNATURES</u>	31
<u>INDEX to EXHIBITS</u>	32
<u>EX-10.1 AMENDED AND RESTATED RESEARCH AGREEMENT</u>	
<u>EX-10.2 Employment and Separation Agreement</u>	
<u>EX-10.3 Employment Agreement</u>	
<u>EX-10.4 Employment Agreement</u>	
<u>EX-10.5 Rental Agreement</u>	
<u>EX-31.1 Certification</u>	
<u>EX-31.2 Certification</u>	
<u>EX-32.1 Certification</u>	

Table of Contents

Unless otherwise specified, all references to the Company, we, us, our, and ourselves refer to Genencor International, Inc. or Genencor International, Inc. and its subsidiaries collectively, as appropriate in the context of the disclosure.

This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements concerning plans, objectives, goals, strategies, future events or performance and all other statements which are other than statements of historical fact, including without limitation, statements containing the words believes, anticipates, expects, estimates, intends, plans, projects, will, may, might, and words of a similar nature. The forward-looking statements contained in this Report reflect the Company's current beliefs and expectations on the date of this Report. Actual results, performance or outcomes may differ materially from those expressed in the forward-looking statements. Some of the important factors which, in the view of the Company, could cause actual results to differ from those expressed in the forward-looking statements are discussed in Part I, Item 2 of this Report and in the Company's Annual Report on Form 10-K for the year ended December 31, 2003. The Company disclaims any obligation to update any forward-looking statement to reflect facts or circumstances after the date hereof.

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS****(Amounts in thousands, except per share data)**

	June 30, 2004	December 31, 2003
Assets		
Current assets:		
Cash and cash equivalents	\$155,084	\$166,551
Trade accounts receivable, net	67,879	58,249
Inventories	75,667	64,159
Other current assets	24,452	36,253
	<hr/>	<hr/>
Total current assets	323,082	325,212
Property, plant and equipment, net	224,120	232,902
Goodwill	29,380	29,380
Intangible assets, net	43,961	47,075
Other assets	74,590	77,853
	<hr/>	<hr/>
Total assets	\$695,133	\$712,422
	<hr/>	<hr/>
Liabilities, Redeemable Preferred Stock and Stockholders' Equity		
Current liabilities:		
Notes payable	\$ 4,999	\$ 5,926
Current maturities of long-term debt	28,249	28,249
Accounts payable and accrued expenses	40,604	49,143
Other current liabilities	18,670	18,850
	<hr/>	<hr/>
Total current liabilities	92,522	102,168
Long-term debt	29,483	58,466
Other long-term liabilities	38,443	39,101
	<hr/>	<hr/>
Total liabilities	160,448	199,735
	<hr/>	<hr/>

Redeemable preferred stock:

7½% cumulative series A preferred stock, without par value, authorized 1 shares,
1 shares issued and outstanding

180,663	177,025
---------	---------

Stockholders' equity:

Common stock, par value \$0.01 per share, 200,000 shares authorized, 61,148 and
60,991 shares issued at June 30, 2004 and December 31, 2003, respectively

611	610
-----	-----

Additional paid-in capital

361,639	359,344
---------	---------

Treasury stock, 1,780 shares at cost at June 30, 2004 and December 31, 2003

(21,030)	(21,030)
----------	----------

Deferred stock-based compensation

(789)	(1,036)
-------	---------

Retained earnings

23,843	589
--------	-----

Accumulated other comprehensive loss

(10,252)	(2,815)
----------	---------

Total stockholders' equity

354,022	335,662
---------	---------

Total liabilities, redeemable preferred stock and stockholders' equity

\$695,133	\$712,422
-----------	-----------

The accompanying notes are an integral part of the condensed consolidated unaudited financial statements.

Table of Contents**GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS****(Amounts in thousands, except per share data)**

	Three months ended June 30,		Six months ended June 30,	
	2004	2003	2004	2003
Revenues:				
Product revenue	\$ 96,173	\$89,744	\$187,712	\$179,782
Fees and royalty revenues	13,759	6,603	16,583	12,226
Total revenues	109,932	96,347	204,295	192,008
Operating expenses:				
Cost of products sold	55,031	51,786	105,496	102,627
Research and development	17,527	16,833	34,407	33,293
Sales, marketing and business development	9,366	7,902	17,686	15,601
General and administrative	9,412	7,982	17,914	15,783
Amortization of intangible assets	1,148	1,498	2,323	2,890
Other (income)/expense	(90)	54	(7,995)	759
Total operating expenses	92,394	86,055	169,831	170,953
Operating income	17,538	10,292	34,464	21,055
Non operating expenses/(income):				
Investment expense		1,018		1,018
Interest expense	1,006	1,569	2,542	3,589
Interest income	(822)	(1,558)	(1,693)	(2,403)
Total non operating expenses/(income)	184	1,029	849	2,204
Income before income taxes	17,354	9,263	33,615	18,851
Provision for income taxes	3,471	1,644	6,723	4,712
Net income	\$ 13,883	\$ 7,619	\$ 26,892	\$ 14,139
Net income available to holders of common stock	\$ 12,064	\$ 5,800	\$ 23,254	\$ 10,501

Earnings per common share:				
Basic	\$ 0.20	\$ 0.10	\$ 0.39	\$ 0.18
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Diluted	\$ 0.20	\$ 0.10	\$ 0.38	\$ 0.18
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Weighted average common shares:				
Basic	59,305	58,570	59,285	58,534
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Diluted	60,826	60,230	61,050	59,515
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

The accompanying notes are an integral part of the condensed consolidated unaudited financial statements.

Table of Contents**GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS**
(Amounts in thousands)

	Six months ended June 30,	
	2004	2003
Cash flows from operating activities:		
Net income	\$ 26,892	\$ 14,139
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	18,128	17,702
Amortization of deferred stock-based compensation	418	554
Loss on disposition of property, plant and equipment		521
Loss from impairment of investment in marketable equity securities		1,018
(Increase) decrease in operating assets:		
Trade accounts receivable	(8,521)	(1,648)
Inventories	(12,122)	2,307
Other assets	10,846	(13,260)
Decrease in operating liabilities:		
Accounts payable and accrued expenses	(5,350)	(4,491)
Other liabilities	(5,210)	(963)
Net cash provided by operating activities	<u>25,081</u>	<u>15,879</u>
Cash flows from investing activities:		
Purchases of property, plant and equipment	(9,456)	(10,553)
Proceeds from sale of business		1,145
Proceeds from note receivable	251	
Assumption of controlling interest in joint venture	3,751	
Payments related to prior acquisition	(632)	
Net cash used in investing activities	<u>(6,086)</u>	<u>(9,408)</u>
Cash flows from financing activities:		
Proceeds from exercise of stock options	1,134	1,876
Proceeds from employee stock purchase plan	833	732
Net (payments on)/proceeds from notes payable of foreign affiliate	(1,772)	91
Payment of long-term debt	(28,126)	(28,123)

	<u> </u>	<u> </u>
Net cash used in financing activities	<u>(27,931)</u>	<u>(25,424)</u>
Effect of exchange rate changes on cash	<u>(2,531)</u>	<u>5,333</u>
Net decrease in cash and cash equivalents	(11,467)	(13,620)
Cash and cash equivalents beginning of period	<u>166,551</u>	<u>169,001</u>
Cash and cash equivalents end of period	<u>\$155,084</u>	<u>\$155,381</u>

The accompanying notes are an integral part of the condensed consolidated unaudited financial statements.

Table of Contents**GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS**
(Amounts in thousands, except per share data)**1 Basis of Presentation**

The condensed consolidated unaudited financial statements should be read in conjunction with the Company's audited consolidated financial statements and related footnotes for the year ended December 31, 2003, as included in the Company's Annual Report on Form 10-K. These interim financial statements have been prepared in conformity with the rules and regulations of the U.S. Securities and Exchange Commission. Certain disclosures normally included in financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations pertaining to interim financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for fair presentation of the interim financial statements have been included therein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year.

2 New Accounting Pronouncements

In December 2003, the Financial Accounting Standards Board (FASB) issued a revision of Statement of Financial Accounting Standards (SFAS) No. 132, *Employers' Disclosures about Pensions and Other Postretirement Benefits*. The revised Statement provides required disclosures for pensions and other postretirement benefit plans and is designed to improve disclosure transparency in financial statements. The revised Statement replaces existing year-end and interim disclosure requirements. This Statement was in effect for the Company's fiscal year ending December 31, 2003 and for quarters beginning thereafter for domestic plans, and is effective for fiscal years ending after June 15, 2004 for the Company's foreign plans.

In May 2004, the FASB issued FASB Staff Position (FSP) No. 106-2, *Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003*. This Position supersedes FSP No. 106-1 of the same title, which was issued in January 2004. FSP No. 106-1 permitted employers that sponsor postretirement benefit plans which provide prescription drug benefits to retirees to make a one-time election to defer accounting for any effects of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. FSP No. 106-2 provides guidance on accounting for the effects of the new Medicare prescription drug legislation by employers whose prescription drug benefits are actuarially equivalent to the drug benefit under Medicare Part D. For all public companies that sponsor one or more plans with more than 100 participants, the Position is effective as of the first interim or annual period beginning after June 15, 2004. The Company does not expect the adoption of FSP No. 106-2 to have a material impact on its financial position or its results of operations.

3 Pension Plans

A summary of the components of net periodic pension cost, a non-cash item, for the six months ended June 30 is as follows:

	2004	2003
Service Cost	\$1,365	\$1,303
Interest Cost	352	313

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Expected return on plan assets	(519)	(338)
Net amortization	<u>13</u>	<u>51</u>
Net periodic pension cost	<u>\$1,211</u>	<u>\$1,329</u>

Table of Contents**4 Earnings Per Share**

SFAS No. 128, Earnings per Share, requires the disclosure of basic and diluted earnings per share. Basic earnings per share is computed based on the weighted average number of common shares outstanding during the period. In arriving at net income available to holders of common stock, undeclared and unpaid dividends on redeemable preferred stock of \$1,819 were deducted from net income for each quarter presented.

Diluted earnings per common share reflects the potential dilution that could occur if dilutive securities and other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income available to holders of common stock of the Company. As a result of stock options outstanding under the Company's 2002 Omnibus Incentive Plan, successor to the Company's Stock Option and Stock Appreciation Right Plan, there were dilutive securities for the three and six months ended June 30, 2004 and 2003. The weighted-average impact of these has been reflected in the calculation of diluted earnings per common share for the respective periods presented.

The following table reflects the calculation of basic and diluted earnings per common share:

	Three months ended June 30,		Six months ended June 30,	
	2004	2003	2004	2003
Net income	\$13,883	\$ 7,619	\$26,892	\$14,139
Less: Accrued dividends on preferred stock	(1,819)	(1,819)	(3,638)	(3,638)
Net income available to holders of common stock	<u>\$12,064</u>	<u>\$ 5,800</u>	<u>\$23,254</u>	<u>\$10,501</u>
Weighted average common shares:				
Basic	59,305	58,570	59,285	58,534
Effect of stock options	<u>1,521</u>	<u>1,660</u>	<u>1,765</u>	<u>981</u>
Diluted	<u>60,826</u>	<u>60,230</u>	<u>61,050</u>	<u>59,515</u>
Earnings per common share:				
Basic	<u>\$ 0.20</u>	<u>\$ 0.10</u>	<u>\$ 0.39</u>	<u>\$ 0.18</u>
Diluted	<u>\$ 0.20</u>	<u>\$ 0.10</u>	<u>\$ 0.38</u>	<u>\$ 0.18</u>

5 Stock-Based Compensation

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Under the provisions of SFAS No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure, the Company has elected to continue to account for stock options using the intrinsic value method in accordance with the provisions of APB Opinion No. 25, Accounting for Stock Issued to Employees.

Table of Contents

Pursuant to SFAS No. 148, *Accounting for Stock Based Compensation Transition and Disclosure*, on a pro forma basis, had the Company's stock option plans been accounted for under the fair value method of SFAS No. 123, the Company's net income and earnings per share would have been reduced to the pro forma amounts shown below:

	Three months ended June 30,		Six months ended June 30,	
	2004	2003	2004	2003
Net income available to holders of common stock- as reported	\$12,064	\$ 5,800	\$23,254	\$10,501
Add: Stock-based employee compensation expense included in reported net income available, net of related tax	108	124	108	286
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effect	<u>(1,376)</u>	<u>(1,324)</u>	<u>(2,874)</u>	<u>(2,624)</u>
Net income available to holders of common stock -pro forma	<u>\$10,796</u>	<u>\$ 4,600</u>	<u>\$20,488</u>	<u>\$ 8,163</u>
Basic - as reported	\$ 0.20	\$ 0.10	\$ 0.39	\$ 0.18
Basic - pro forma	\$ 0.18	\$ 0.08	\$ 0.34	\$ 0.14
Diluted - as reported	\$ 0.20	\$ 0.10	\$ 0.38	\$ 0.18
Diluted - pro forma	\$ 0.18	\$ 0.08	\$ 0.33	\$ 0.14

The pro forma figures in the preceding table may not be representative of pro forma amounts in future quarters.

6 Inventories

Inventories consist of the following:

	June 30, 2004	December 31, 2003
Raw materials	\$ 8,710	\$ 7,682
Work-in-progress	10,861	9,106
Finished goods	<u>56,096</u>	<u>47,371</u>
Inventories	<u>\$75,667</u>	<u>\$64,159</u>

The Company sustained damage to its finished bioproducts inventory in the second quarter of 2003 as a result of an accident in a third party warehouse in Rotterdam, the Netherlands. At the end of the first quarter of 2004, the Company reached a final settlement of its accident-related claim with its insurer totaling approximately \$21,000 and recorded a net gain of \$8,290.

7 Goodwill and Other Intangible Assets

In accordance with the provisions of SFAS No. 142, *Goodwill and Other Intangible Assets* the Company does not amortize goodwill or other intangible assets with indefinite useful lives. The Company has identified such other indefinite-lived intangible assets to include certain previously acquired technology. The Company periodically evaluates its indefinite-lived intangible assets for impairment in accordance with the provisions of SFAS No. 142. The Company also has other intangible assets, such as patents, licenses, and customer lists, which will continue to be amortized using the straight-line method. These assets are expected to have no residual value once they are fully amortized.

Table of Contents

The following table summarizes the changes in each major class of intangible assets from January 1, 2004 through June 30, 2004:

	Intangible Assets			Goodwill
	Technology	Other Amortizable Assets	Total	
Balances, January 1, 2004	\$ 15,831	\$ 73,591	\$ 89,422	\$29,380
Foreign currency translation and other adjustments	(6)	(1,120)	(1,126)	
Balances, June 30, 2004	\$ 15,825	72,471	88,296	\$29,380
Less: Accumulated amortization		(44,335)	(44,335)	
Intangible assets, net		\$ 28,136	\$ 43,961	

Estimated fiscal year amortization expense is as follows:

2004	\$4,600
2005	4,100
2006	3,800
2007	2,500
2008	1,300

8 Stockholders Equity

Accumulated other comprehensive loss consists of the following:

	Foreign Currency Translation Adjustment	Marketable Securities Valuation Adjustment	Accumulated Other Comprehensive Loss
Balances, December 31, 2003	\$(2,350)	\$ (465)	\$ (2,815)
Current period change	(6,860)	(577)	(7,437)

Balances, June 30, 2004	<u>\$(9,210)</u>	<u>\$(1,042)</u>	<u>\$(10,252)</u>
-------------------------	------------------	------------------	-------------------

The change in the foreign currency translation adjustment for the six months ended June 30, 2004 relates primarily to Company operations with functional currencies in Euros. The change in the marketable securities valuation adjustment for the six months ended June 30, 2004 of \$577 (\$916 pre-tax) relates to unrealized holding losses on the Company's available-for-sale securities.

9 Income Taxes

The effective income tax rate for the six months ended June 30, 2004 was 20%, compared to 25% for the six months ended June 30, 2003, which reflects the Company's assessment of its annual effective income tax rate. Factors affecting the Company's estimated annual effective income tax rate include increased operating expenses, the statutory income tax rates in foreign jurisdictions and the relative amount of income in each jurisdiction, certain items which are not deductible for tax purposes, and research and experimentation tax credits. In addition, the estimated annual effective rate for the six months ended June 30, 2003 included the effect of estimated valuation allowances, since the Company did not anticipate having the ability to utilize certain tax credits.

Table of Contents**10 Fees and Royalty Revenues**

The increase in fees and royalty revenues of \$4,357 for the six months ended June 30, 2004 from the six months ended June 30, 2003 was primarily driven by the technology transfer described in Note 12, Technology Transfer, and a reduction in funding from the Company's strategic alliance with the Dow Corning Corporation.

11 Segment Reporting

In accordance with SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, segments were determined based on products and services provided by each segment. Accounting policies for the segments are the same as those described in Note 1, Summary of Significant Accounting Policies of the Company's Annual Report on Form 10-K for the year ended December 31, 2003. Performance of the segments is evaluated based on operating income of the segment. No items below operating income are allocated to the segments. The Company accounts for transactions, if any, between the segments as though they were transactions with third parties at approximate market prices. There were no material inter-segment transactions in the periods presented. The Company's managerial financial reporting reflects two operating segments: Bioproducts and Health Care.

The Bioproducts segment develops and delivers products and services to the industrial, consumer and agri-processing markets to a global customer base. All of the Company's current product revenues are derived from this segment.

The Health Care segment is focused on expanding the Company's current technology and product platforms into the health care market. This segment is primarily engaged in the performance of research and development, the securing of intellectual property and the establishment of strategic investments and collaborations.

The following table provides information by business segment:

For the three months ended June 30, 2004

	Bioproducts	Health Care	Segment Subtotal	Corporate and Other	Consolidated Totals
Product revenue	\$96,173	\$	\$ 96,173	\$	\$ 96,173
Fees and royalty revenues	3,759	10,000	13,759		13,759
Total revenues	99,932	10,000	109,932		109,932
Research and development	12,198	5,329	17,527		17,527
Operating income	14,212	3,216	17,428	110	17,538

For the three months ended June 30, 2003

	Bioproducts	Health Care	Segment Subtotal	Corporate and Other	Consolidated Totals
Product revenue	\$89,744	\$	\$ 89,744	\$	\$89,744
Fees and royalty revenues	6,453	150	6,603		6,603

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Total revenues	96,197	150	96,347		96,347
Research and development	10,914	5,919	16,833		16,833
Operating income/(loss)	17,737	(7,536)	10,201	91	10,292

11

Table of Contents**For the six months ended June 30, 2004**

	Bioproducts	Health Care	Segment Subtotal	Corporate and Other	Consolidated Totals
Product revenue	\$ 187,712	\$	\$ 187,712	\$	\$ 187,712
Fees and royalty revenues	6,358	10,225	16,583		16,583
Total revenues	194,070	10,225	204,295		204,295
Research and development.	23,174	11,233	34,407		34,407
Operating income/(loss)	38,154	(3,581)	34,573	(109)	34,464

For the six months ended June 30, 2003

	Bioproducts	Health Care	Segment Subtotal	Corporate and Other	Consolidated Totals
Product revenue	\$ 179,782	\$	\$ 179,782	\$	\$ 179,782
Fees and royalty revenues	12,001	225	12,226		12,226
Total revenues	191,783	225	192,008		192,008
Research and development.	21,234	12,059	33,293		33,293
Operating income/(loss)	36,795	(15,442)	21,353	(298)	21,055

The following table provides a reconciliation of segment information to total consolidated information:

	Three months ended June 30,		Six months ended June 30,	
	2004	2003	2004	2003
Net income:				
Operating income/(loss) for reportable segments	\$ 17,428	\$ 10,201	\$ 34,573	\$ 21,353
Other (income)/expense	(110)	(91)	109	298
Investment expense		1,018		1,018
Interest expense	1,006	1,569	2,542	3,589
Interest (income)	(822)	(1,558)	(1,693)	(2,403)
Provision for/(benefit from) income taxes	3,471	1,644	6,723	4,712
Consolidated net income	<u>\$ 13,883</u>	<u>\$ 7,619</u>	<u>\$ 26,892</u>	<u>\$ 14,139</u>

12 Technology Transfer

During March 2004, the Company's Health Care segment sold its therapeutic vaccine program to Innogenetics N.V. Upon transfer of certain intellectual property, contractual relationships and technologies to Innogenetics, the Company recognized fees during the quarter ended June 30, 2004 totaling \$10,000. The Company expects to receive further payments as development milestones are achieved. Once products are commercialized, the Company would also receive royalty payments on future product sales.

13 Joint Venture

On April 1, 2004 the Company assumed majority ownership and controlling interest of the Company's eight-year-old joint venture with Kyowa Hakko Kogyo Co. Ltd., as a result of the joint venture's partial repurchase of a portion of the other owner's share. This venture has been named Genencor Kyowa Co. Ltd. The financial position, results of operations and cash flows of the joint venture have been included in the Company's consolidated financial statements beginning April 1, 2004.

Table of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the notes to those statements included in our Annual Report on Form 10-K for the year ended December 31, 2003 and the condensed consolidated unaudited financial statements and related notes included elsewhere in this Report.

Executive Summary

Leveraging over twenty years of experience, we use our molecular technologies to develop products and deliver services for varied markets, some on a global basis. Since our research and commercial expertise and competencies are at the molecular level we can produce products and deliver services to many different types of industries. Our current revenues result primarily from the sale of enzyme products as ingredients or processing aids to the cleaning, textiles, sweeteners, fermentation alcohol and food, feed and specialties markets, and from research funding, fees and royalties. In the three months ended June 30, 2004, we expended \$12.2 million on our Bioproducts research and development programs. In addition to developing products for our current Bioproduct markets, we are now involved in Bioproduct research projects and programs that are directed toward providing new products and services in the emerging fields of biomaterials, biochemicals and nanobiotechnology. Furthermore, we expended \$5.3 million in the second quarter of 2004 on our Health Care research and development programs. We believe that this diversification of our research and development expenditures will increase the probability of achieving success in our commercial portfolio and result in increased value for our stockholders.

Overall, for the three months ended June 30, 2004, net income available to common stockholders was \$12.1 million, or \$0.20 per diluted share, compared to \$5.8 million or \$0.10 per diluted share during the same period in 2003. Product revenues increased by 7% to \$96.2 million, compared to \$89.7 million in the second quarter of 2003. Total revenues for the three months ended June 30, 2004 were \$109.9 million, compared to \$96.3 million for the same period in 2003. Fees and royalty revenues were \$13.8 million in the second quarter as compared to \$6.6 million in the prior year, driven primarily by the recognition of fees totaling \$10.0 million from the technology transfer of our therapeutic vaccine program to Innogenetics N.V. For the three months ended June 30, 2004, we generated \$17.5 million in operating income and \$18.8 million in cash flow from operations. We also invested \$5.7 million in purchases of property, plant and equipment and recognized the cash and cash equivalents of Genencor Kyowa Co. Ltd. of \$3.8 million at April 1, 2004 due to our assumption of a 70% interest in that venture. The financial position, results of operations and cash flows of the joint venture have been included in our consolidated financial statements beginning April 1, 2004.

For the six months ended June 30, 2004, total revenues were \$204.3 million, compared to \$192.0 million for the same period in 2003. Net income available to common stockholders was \$23.3 million, or \$0.38 per diluted share for the six months ended June 30, 2004, compared to \$10.5 million or \$0.18 per diluted share for that same period in 2003.

Our Bioproducts segment continues to generate all of our product revenues. In the three months ended June 30, 2004, our Bioproducts segment set a quarterly product revenue record for the Company, driven by increases in all product revenue categories. Particular strength was seen in the fermentation alcohol, sweeteners and food and specialties markets. Globally, most regions reported increased sales, with Asia Pacific reflecting double-digit growth. We manufacture our products at our eight Bioproducts manufacturing facilities located in the United States, Finland, Belgium, China and Argentina. We conduct our sales and marketing activities through our direct sales organizations in the United States, the Netherlands, Singapore, Japan, China, United Kingdom, Argentina and Brazil and through other distribution channels in selected markets and geographies. For the three months ended June 30, 2004, we

derived approximately 55% of our revenues from our foreign operations.

During the second quarter, we also continued to make significant progress on new applications within the Bioproducts segment. We moved closer to the commercialization of new products for the growing biodefense industry. We manufactured sample quantities of enzymes that neutralize sarin nerve gas and other organophosphate-based agents and are providing samples to formulators for development into foams, sprays and detergents for use by both military and civilian first responders, such as fire departments, police and hazardous material response teams. The enzymes were developed in collaboration with the U.S. Army Edgewood Chemical Biological Center. We expect to receive final regulatory approval from the U.S. Environmental Protection Agency and we expect to commercialize these products in the fourth quarter of

Table of Contents

2004. In addition, we continued making progress toward commercialization of proprietary enzyme products that effectively reduce prion infectivity. Prions are widely seen as the causative agent of Bovine Spongiform Encephalopathy (commonly known as mad cow disease), and its human variant, Cruetzfeldt-Jakob Disease. Concerning Silicon Biotechnology platform, we entered into a two-year extension, effective January 1, 2004, of our collaboration with the Dow Corning Corporation focusing on biosensors and other novel products. Efforts also continued on other Bioproducts projects, including personal care and the conversion of biomass to fuel ethanol.

In our Health Care segment, we recognized \$10.0 million in fees during the second quarter of 2004 from the technology transfer of our therapeutic vaccine program to Innogenetics N.V. As more completely discussed under the heading Technology Transfer within Item 2 of this Report, we sold our therapeutic vaccine program to Innogenetics in March 2004. During the second quarter, we completed the transfer to Innogenetics of sponsorship of the investigational new drug application (IND) and Phase I clinical trial for our lead hepatitis B product candidate, plus intellectual property, research compounds and various third party relationships. This transaction has the potential to generate additional milestone and royalty revenues for us in the future. The Health Care segment is now focused entirely on discovery, in-licensing and development of therapeutic products for the oncology market.

Accordingly, our Health Care segment continued to make progress during the second quarter focusing its attention and resources on targeted cancer biotherapeutics. As previously announced, we advanced our first product candidate for treating cancer into IND-enabling development earlier this year. Based upon the Antibody Directed Enzyme Prodrug Therapy (ADEPT) platform, the lead product candidate will initially target significant unmet medical needs in colorectal carcinoma. The preliminary timeline anticipates filing an IND in late 2005 with clinical trials to follow thereafter.

We are pleased with our strong financial performance during the second quarter and for the first six months of 2004. As more completely discussed under the heading Warehouse Inventory Loss within Item 2 of this Report, we are also pleased to have settled our insurance claim from last year's third-party warehouse accident during the first quarter, resulting in a net gain of \$8.3 million, which is included in other income for the six months ended June 30, 2004.

Results of Operations

Comparison of the Three Months Ended June 30, 2004 and 2003

Revenues. Total revenues for the three-month period ended June 30, 2004 increased \$13.6 million, or 14%, to \$109.9 million from the three-month period ended June 30, 2003, due to increases in product revenues and fees and royalty revenues.

Product Revenues. Product revenues for the three months ended June 30, 2004 increased \$6.5 million, or 7%, to \$96.2 million from the three months ended June 30, 2003. For the three months ended June 30, 2004, unit volume/mix increased 6% and the impact of foreign currency, primarily the Euro, increased revenues 3% while average prices fell 2%. Volume/mix increased primarily in our sweeteners, fermentation alcohol, textiles, cleaning and food and specialties markets.

Regionally, North American product revenues for the three months ended June 30, 2004 increased \$2.6 million, or 7%, to \$41.7 million from the three months ended June 30, 2003, driven primarily by increased sales to our fermentation alcohol, sweeteners, food, feed and specialties and textiles markets, partially offset by decreased sales to our cleaning markets. Product revenues in Europe, Africa and the Middle East for the three months ended June 30, 2004 increased \$3.0 million, or 8%, to \$38.8 million from the three months ended June 30, 2003, driven primarily by increased sales to our cleaning, textiles and sweeteners markets, partially offset by decreased sales to our fermentation

alcohol and food, feed and specialties markets. Our product revenues in the Asia Pacific region increased \$1.8 million, or 16%, to \$13.1 million for three months ended June 30, 2004 from the three months ended June 30, 2003 due primarily to increased sales to our food, feed and specialties, sweeteners and cleaning markets, partially offset by decreased sales to our textiles markets. Our product revenues in Latin America for the three months ended June 30, 2004 decreased \$0.9 million, or 26%, to \$2.6 million from the three months ended June 30, 2003, primarily due to decreased sales to our cleaning, sweeteners, food, feed and specialties markets, partially offset by increased sales to our textiles markets.

Fees and Royalty Revenues. Fees and royalty revenues increased \$7.2 million, to \$13.8 million, for the three months ended June 30, 2004 from the three months ended June 30, 2003, primarily due to the recognition of fees totaling \$10.0

Table of Contents

million from the sale of our therapeutic vaccine program to Innogenetics N.V., as more completely discussed in Technology Transfer within Item 2 of this Report.

Funded research revenues for the three months ended June 30, 2004 decreased \$2.7 million, or 44%, to \$3.4 million from the three months ended June 30, 2003. Revenues generated by research funding result from collaborative agreements with various parties, including the U.S. Government, whereby we perform research activities and receive revenues that partially reimburse us for expenses incurred. Under such agreements, we retain a proprietary interest in the products and technology developed.

Our funded research revenue as it relates to U.S. Government collaborations increased \$0.8 million, or 47%, to \$2.5 million for the three months ended June 30, 2004 from the three months ended June 30, 2003 primarily due to funding provided by the National Renewable Energy Laboratory to develop an enzymatic process to convert biomass into ethanol. Funded research revenues provided by customers decreased \$3.5 million, or 80%, to \$0.9 million for the three months ended June 30, 2004 from the three months ended June 30, 2003, due primarily to the reduction in funding from our strategic alliance with the Dow Corning Corporation. During the second quarter, we renewed our Silicon Biotechnology collaboration with the Dow Corning Corporation by agreeing to a two-year extension, effective January 1, 2004.

Royalties decreased \$0.1 million, or 25%, to \$0.3 million for the three months ended June 30, 2004 from the three months ended June 30, 2003, due primarily to the timing of customer royalty payments that are based on the sales of the customers' products produced using our technology.

All other fees increased \$10.0 million to \$10.1 million for the three months ended June 30, 2004 from the three months ended June 30, 2003. This increase was primarily driven by the recognition of \$10.0 million from the technology transfer of our therapeutic vaccine program to Innogenetics N.V., as more completely discussed in Technology Transfer within Item 2 of this Report.

Operating Expenses

Cost of Products Sold. Cost of products sold increased \$3.3 million, or 6%, to \$55.0 million for the three months ended June 30, 2004 from the three months ended June 30, 2003. Our expanded sales volume/mix increased costs \$1.9 million, along with increases due to the impact of the U.S. Dollar against foreign currencies, primarily the Euro, of \$0.9 million, and an increase in unit production costs of approximately \$0.4 million.

Gross Profit and Margins from Products Sold. Gross profit from products sold increased \$3.3 million, or 9%, to \$41.2 million for the three months ended June 30, 2004 from the three months ended June 30, 2003, and gross margin increased to 42.8% for the three months ended June 30, 2004 from 42.3% for the three months ended June 30, 2003. The overall increase was primarily driven by favorable product volume/mix, partially offset by a reduction in average price. Our gross profit was also benefited by a \$1.4 million increase due to the impact of the U.S. Dollar against foreign currencies, primarily the Euro.

Research and Development. Research and development expenses primarily consist of the personnel-related, consulting, and facilities costs incurred in connection with our research activities conducted in Palo Alto, California and Leiden, the Netherlands. These expenses increased \$0.7 million, or 4%, to \$17.5 million for the three months ended June 30, 2004 from the three months ended June 30, 2003, due primarily to increases in personnel-related costs, including salaries, benefits and travel expenses of \$0.4 million, supply costs of \$0.2 million and facilities costs of \$0.3 million, partially offset by a decrease in outside services of \$0.2 million. As a part of total research and development expenses, estimated expenses related to research collaborations partially funded by customers increased \$0.7 million, or 23%, to \$3.8 million for the three months ended June 30, 2004 from the three months ended June 30,

2003.

Sales, Marketing and Business Development. Sales, marketing and business development expenses primarily consist of the personnel-related and marketing costs incurred by our global sales force. These expenses increased \$1.5 million, or 19%, to \$9.4 million for the three months ended June 30, 2004 from the three months ended June 30, 2003, due primarily to increases in personnel-related costs, including salaries, benefits and travel expenses of \$0.9 million, outside services of \$0.3 million, facilities costs of \$0.1 million and increased insurance, tax and royalty expenses of \$0.2 million.

General and Administrative. General and administrative expenses include the costs of our corporate executive, finance, information technology, legal, human resources, and communications functions. In total, these expenses increased \$1.4 million, or 18%, to \$9.4 million for the three months ended June 30, 2004 from the three months ended June 30, 2003, due

Table of Contents

primarily to increases in outside services of \$1.0 million and in personnel-related costs, including salaries, benefits, travel expenses of \$0.3 million and incentive compensation of \$0.2 million.

Amortization of Intangible Assets. We amortize our definite-lived intangible assets, consisting of patents, licenses, customer lists and other contractual agreements on a straight-line basis over their estimated useful lives. Amortization expense decreased \$0.4 million, or 27%, to \$1.1 million for the three months ended June 30, 2004 from the three months ended June 30, 2003. This decrease was primarily due to certain intangible assets becoming fully amortized at year-end 2003.

Other Income and Expense. Other expense and income relates primarily to foreign currency exchange gains and losses on transactions denominated in other than the functional currency of the entity in which the transaction occurred. Other income for the three months ended June 30, 2004 was \$0.1 million as compared with other expense of \$0.1 million for the three months ended June 30, 2003.

Non Operating Expense and Income

Investment Expense. We recorded an investment loss of \$1.0 million in the three months ended June 30, 2003, as a result of our assessment of an other than temporary decline in the fair market value of an investment in certain common stock. There was no such investment income or loss in the three months ended June 30, 2004.

Interest Income. Interest income decreased \$0.8 million, or 50%, to \$0.8 million for the three months ended June 30, 2004 from the three months ended June 30, 2003. The decrease in interest income was primarily due to interest received on a tax refund claim in the second quarter of 2003.

Income Taxes. The effective income tax rate for the three months ended June 30, 2004 was 20%, compared to 18% for the three months ended June 30, 2003, which reflects our assessment of the annual effective income tax rate. Factors affecting our estimated annual effective income tax rate include operating expense increases, the statutory income tax rates in foreign jurisdictions and the relative amount of income in each jurisdiction, certain items which are not deductible for tax purposes, and research and experimentation tax credits. In addition, the estimated annual effective rate in the three months ended June 30, 2003 included the effect of estimated valuation allowances, since we did not anticipate having the ability to utilize certain tax credits.

Comparison of the Six Months Ended June 30, 2004 and 2003

Revenues. Total revenues for the six months ended June 30, 2004 increased \$12.3 million, or 6%, to \$204.3 million from the six months ended June 30, 2003, due to increases in both product revenues and fees and royalty revenues.

Product Revenues. Product revenues in the six months ended June 30, 2004 increased \$7.9 million, or 4%, to \$187.7 million from the six months ended June 30, 2003. For the six months ended June 30, 2004, unit volume/mix increased 2% and the impact of foreign currency, primarily the Euro, increased revenues 4%, while average prices fell 2%. Volume/mix increased in our sweeteners, fermentation alcohol, cleaning and textiles markets, partially offset by a decrease in our food, feed and specialties markets.

Regionally, North American product revenues for the six months ended June 30, 2004 increased \$1.5 million, or 2%, to \$78.3 million from the six months ended June 30, 2003, driven primarily by increased sales to our fermentation alcohol, sweeteners and our food, feed and specialties markets, partially offset by decreased sales to our cleaning and textiles markets. Product revenues in Europe, Africa and the Middle East for the six months ended June 30, 2004 increased \$7.0 million, or 10%, to \$78.8 million from the six months ended June 30, 2004, driven primarily by increased sales to our cleaning, textiles and sweeteners markets, partially offset by decreased sales to our fermentation

alcohol and food, feed and specialties markets. Product revenues in the Asia Pacific region increased \$0.3 million, or 1%, to \$24.7 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, due to increased sales to our food, feed and specialties, sweeteners and fermentation alcohol markets, partially offset by decreased sales to our cleaning and textiles markets. Our product revenues in Latin America for the six months ended June 30, 2004 decreased \$0.9 million, or 13%, to \$5.9 million from the six months ended June 30, 2003, due primarily to decreased sales to our food, feed and specialties, sweeteners and cleaning markets, partially offset by increased sales to our textiles markets.

Table of Contents

Fees and Royalty Revenues. Fees and royalty revenues increased \$4.4 million, or 36%, to \$16.6 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, due to the recognition of fees totaling \$10.0 million from the sale of our therapeutic vaccine program to Innogenetics N.V., as more completely discussed in Technology Transfer within Item 2 of this Report.

Funded research revenues decreased \$5.7 million, or 51%, to \$5.5 million for the six months ended June 30, 2004 from the six months ended June 30, 2003. Revenues generated by research funding result from collaborative agreements with various parties, including the U.S. Government, whereby we perform research activities and receive revenues that partially reimburse us for expenses incurred. Under such agreements, we retain a proprietary interest in the products and technology developed.

Our funded research revenue as it relates to U.S. Government collaborations increased \$0.7 million, or 25%, to \$3.5 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, primarily due to funding provided by the National Renewable Energy Laboratory to develop an enzymatic process to convert biomass into ethanol. Funded research revenues provided by customers decreased \$6.4 million, or 76%, to \$2.0 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, due primarily to the reduction in funding from our strategic alliance with the Dow Corning Corporation. During the second quarter, we renewed our Silicon Biotechnology collaboration with the Dow Corning Corporation by agreeing to a two-year extension, effective January 1, 2004.

Royalties increased \$0.1 million, or 11%, to \$1.0 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, due primarily to the timing of customer royalty payments that are based on the sales of the customers' products produced using our technology.

All other fees increased \$10.0 million to \$10.1 million for the six months ended June 30, 2004 from the six months ended June 30, 2003. This increase was primarily driven by the recognition of \$10.0 million from the technology transfer of our therapeutic vaccine program to Innogenetics N.V., as more completely discussed in Technology Transfer within Item 2 of this Report.

Operating Expenses

Cost of Products Sold. Cost of products sold increased \$2.9 million, or 3%, to \$105.5 million for the six months ended June 30, 2004 from the six months ended June 30, 2003. Our expanded product volume/mix increased costs \$1.4 million, along with an increase of \$4.0 million due to the impact of the U.S. Dollar against foreign currencies, primarily the Euro. These increases were partially offset by a \$2.5 million decrease due to lower unit production costs for the period.

Gross Profit and Margins from Products Sold. Gross profit from products sold increased \$5.0 million, or 6%, to \$82.2 million for the six months ended June 30, 2004 from the six months ended June 30, 2003 and gross margin increased to 43.8% for the six months ended June 30, 2004 from 42.9% for the six months ended June 30, 2003. The overall increase was primarily driven by favorable product volume/mix and unit production costs, partially offset by a reduction in average price. Our gross profit was also benefited by a \$4.0 million increase due to the impact of the U.S. Dollar against foreign currencies, primarily the Euro.

Research and Development. Research and development expenses increased \$1.1 million, or 3%, to \$34.4 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, primarily due to increases in personnel-related costs, including salaries, benefits and travel expenses of \$0.8 million, supply costs of \$0.3 million and facilities costs of \$0.5 million, partially offset by decreases in outside services of \$0.5 million and incentive compensation of \$0.2 million. As a part of total research and development expenses, estimated expenses related to

research collaborations partially funded by customers decreased \$0.4 million, or 6%, to \$5.8 million for the six months ended June 30, 2004 from the six months ended June 30, 2003.

Sales, Marketing and Business Development. Sales, marketing and business development expenses increased \$2.1 million, or 13%, to \$17.7 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, primarily due to increases in personnel-related costs, including salaries, benefits and travel expenses of \$1.5 million, supply costs of \$0.1 million, insurance, tax and royalty expenses of \$0.2 million, and an increase in the provision for doubtful accounts at our Chinese affiliate of \$0.2 million.

General and Administrative. General and administrative expenses increased \$2.1 million, or 13%, to \$17.9 million for the six months ended June 30, 2004 from the six months ended June 30, 2003, due primarily to increases in outside services of \$1.7 million, personnel-related costs, including salaries, benefits, and travel expenses, of \$0.2 million and incentive compensation of \$0.1 million.

Table of Contents

Amortization of Intangible Assets. Amortization expense decreased \$0.6 million, or 21%, to \$2.3 million for the six months ended June 30, 2004 from the six months ended June 30, 2003. This decrease was primarily due to certain intangible assets becoming fully amortized at year-end 2003.

Other Income and Expense. Other income for the six months ended June 30, 2004 was \$8.0 million as compared to \$0.8 million of other expense for the six months ended June 30, 2003. This difference in income of \$8.8 million was primarily driven by the \$8.3 million net gain recorded during the quarter ended March 31, 2004, resulting from the final settlement of our insurance claim related to the warehouse accident in Rotterdam, the Netherlands that occurred in the second quarter of 2003.

Non Operating Expense and Income

Investment Expense. We recorded an investment loss of \$1.0 million in the six months ended June 30, 2003, as a result of our assessment of an other than temporary decline in the fair market value of an investment in certain common stock. There was no such investment income or loss in the six months ended June 30, 2004.

Interest Income. Interest income decreased \$0.7 million, or 29%, to \$1.7 million for the six months ended June 30, 2004 from the six months ended June 30, 2003. The decrease in interest income was primarily due to interest received on a tax refund claim in the second quarter of 2003.

Income Taxes. The effective income tax rate for the six months ended June 30, 2004 was 20%, compared to 25% for the six months ended June 30, 2003, which reflects our assessment of our annual effective income tax rate. Factors affecting our estimated annual effective income tax rate include operating expense increases, the statutory income tax rates in foreign jurisdictions and the relative amount of income in each jurisdiction, certain items which are not deductible for tax purposes, and research and experimentation tax credits. In addition, the estimated annual effective rate for the six months ended June 30, 2003 included the effect of estimated valuation allowances, since we did not anticipate having the ability to utilize certain tax credits.

Financial Results by Segment

Our managerial financial reporting provides information that aligns with the two-segment structure of Bioproducts and Health Care. Accordingly, we have provided financial data in this financial segment reporting for the three months and the six months ended June 30, 2004 and 2003.

The Bioproducts segment develops and delivers products and services for the industrial, consumer and agri-processing markets to a global customer base. All of our current product revenues are derived from this segment. For the three months ended June 30, 2004, the Bioproducts segment achieved operating income of \$14.2 million as compared to operating income of \$17.7 million for the three months ended June 30, 2003. For the six months ended June 30, 2004, the Bioproducts segment achieved operating income of \$38.2 million as compared to operating income of \$36.8 million for the six months ended June 30, 2003.

The Health Care segment is primarily engaged in the performance of research and development, securing intellectual property and the establishment of strategic investments and collaborations in support of our product objectives in the health care market. For the three months ended June 30, 2004, the Health Care segment experienced operating income of \$3.2 million as compared to an operating loss of \$7.5 million for the three months ended June 30, 2003. This was primarily due to the recognition of fees totaling \$10.0 million from the technology transfer of our therapeutic vaccine program to Innogenetics N.V. during the quarter ended June 30, 2004. For the six months ended June 30, 2004, the Health Care segment experienced an operating loss of \$3.6 million as compared to an operating loss of \$15.4 million for the six months ended June 30, 2003.

Joint Venture

On April 1, 2004 we assumed majority ownership and controlling interest of our eight-year-old joint venture with Kyowa Hakko Kogyo Co. Ltd., as a result of the joint venture's partial repurchase of a portion of the other owner's share. This venture has been

Table of Contents

named Genencor Kyowa Co. Ltd. The financial position, results of operations and cash flows of the joint venture have been included in our consolidated financial statements beginning April 1, 2004.

Technology Transfer

During March 2004, our Health Care segment sold its therapeutic vaccine program to Innogenetics N.V. Upon transfer of certain intellectual property, contractual relationships and technologies to Innogenetics, we recognized fees during the quarter ended June 30, 2004 totaling \$10.0 million. We expect to receive further payments as development milestones are achieved. Once products are commercialized, we would also receive royalty payments on future product sales.

Warehouse Inventory Loss

We sustained damage to our finished bioproducts inventory in the second quarter of 2003 as a result of an accident in a third party warehouse in Rotterdam, the Netherlands. At the end of the first quarter of 2004, we reached a final settlement of our accident-related claim with our insurer totaling approximately \$21.0 million and recorded a net gain of \$8.3 million.

Liquidity and Capital Resources

Our funding needs consist primarily of capital expenditures, research and development activities, sales and marketing expenses, and general corporate purposes. We have financed our operations primarily through cash from the sale of products, the sale of stock, research and development funding from partners, government grants, and short-term and long-term borrowings.

We believe that our current cash and cash equivalent balances plus funds to be provided from our current year operating activities, together with those available under our lines of credit, will satisfy our funding needs over the next twelve months. Factors that could negatively impact our cash position include, but are not limited to, future levels of product revenues, fees and royalty revenues, expense levels, capital expenditures, acquisitions, and foreign currency exchange rate fluctuations.

As of June 30, 2004, cash and cash equivalents totaled \$155.1 million. The funds were invested in short-term instruments, including A-1/P1 and A-2/P2 rated commercial paper, AAA and AA rated medium term notes, institutional money market funds, auction rate preferred securities and bank deposits.

Cash provided by operations was \$25.1 million and \$15.9 million for the six months ended June 30, 2004 and 2003, respectively. The increase of \$9.2 million in 2004 from 2003 was generated principally by the increase in operating income, net of non-cash items such as depreciation and amortization, partially offset by changes in operating assets and liabilities.

Cash used in investing activities was \$6.1 million and \$9.4 million for the six months ended June 30, 2004 and 2003, respectively. This decrease in cash used of \$3.3 million was driven primarily by the recognition of the cash and cash equivalents of Kyowa Hakko Kogyo Co. Ltd. of \$3.8 million at April 1, 2004 due to our assumption of a controlling interest in the venture. This venture has been named Genencor Kyowa Co. Ltd. Capital expenditures for the six months ended June 30, 2004 were \$9.5 million compared with \$10.6 million in 2003. A significant portion of this spending included process improvement projects at our manufacturing and research and development facilities and information technology enhancements. During the six months ended June 30, 2003, construction continued on our facility for the clinical-scale manufacture of human therapeutic proteins in Rochester, New York. Construction of this facility was completed during the third quarter of 2003.

Cash used in financing activities was \$27.9 million and \$25.4 million for the six months ended June 30, 2004 and 2003, respectively, which reflects our \$28.0 million annual installment payments made on our senior debt in each period. The increase of \$2.5 million during the six months ended June 30, 2004 was primarily driven by payments on notes payable for one of the Company's foreign affiliates. While we are permitted to pay dividends to our common stockholders, we currently intend to utilize our resources to finance the expansion of our business. Any future determination to pay cash dividends to our common stockholders will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements, general business conditions and other factors that the board of directors may deem relevant, including covenants in our debt instruments that may limit our ability to declare and pay cash dividends on

Table of Contents

our capital stock. Covenants in our senior note agreement restrict the payment of dividends or other distributions in cash or other property to the extent the payment puts us in default of these covenants. Such covenants include, but are not limited to, maintaining a debt to total capitalization of no greater than 55% and a maximum ratio of debt to earnings before interest, taxes, depreciation and amortization (EBITDA) of 3.5:1.

At June 30, 2004, we had a \$40.0 million revolving credit facility with a syndicate of banks, which is available for general corporate purposes. The credit facility, which consists of a credit agreement, makes available to the Company \$40.0 million of committed borrowings and expires on December 23, 2006. The credit facility fees were 0.25% on the amount of unborrowed principal under the agreement for the three months ended June 30, 2004. As of June 30, 2004, there were no borrowings under the facility.

Our long-term debt consists primarily of the 6.82% senior notes issued in 1996 to certain institutional investors. The remaining principal amount of these notes is \$56.0 million. Annual installment payments of \$28.0 million commenced on March 30, 2002. We are currently in compliance with the financial covenants included in the senior note agreement.

New Accounting Pronouncements

In December 2003, the FASB issued a revision of SFAS No. 132, *Employers' Disclosures about Pensions and Other Postretirement Benefits*. The revised Statement provides required disclosures for pensions and other postretirement benefit plans and is designed to improve disclosure transparency in financial statements. The revised Statement replaces existing year-end and interim disclosure requirements. This Statement was in effect for our fiscal year ending December 31, 2003 and for quarters beginning thereafter for domestic plans, and is effective for fiscal years ending after June 15, 2004 for our foreign plans.

In May 2004, the FASB issued FASB Staff Position (FSP) No. 106-2, *Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003*. This Position supersedes FSP No. 106-1 of the same title, which was issued in January 2004. FSP No. 106-1 permitted employers that sponsor postretirement benefit plans which provide prescription drug benefits to retirees to make a one-time election to defer accounting for any effects of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. FSP No. 106-2 provides guidance on accounting for the effects of the new Medicare prescription drug legislation by employers whose prescription drug benefits are actuarially equivalent to the drug benefit under Medicare Part D. For all public companies that sponsor one or more plans with more than 100 participants, the Position is effective as of the first interim or annual period beginning after June 15, 2004. We do not expect the adoption of FSP No. 106-2 to have a material impact on our financial position or our results of operations.

Market Risk

Foreign currency risk and interest rate risk are the primary sources of our market risk. Foreign operations, mainly denominated in Euros, accounted for approximately 55% of our revenues for the six months ended June 30, 2004. We believe that we mitigate this risk by locating our manufacturing facilities so that the costs are denominated in the same currency as our product revenues. We may manage the foreign currency exposures that remain through the use of foreign currency forward contracts, currency options and off-setting currency positions in assets and liabilities where deemed appropriate. We do not use these instruments for speculative purposes. There was no material foreign currency gains in connection with these types of contracts recorded in the statement of operations for the six months ended June 30, 2004.

As of June 30, 2004, cash and cash equivalents totaled \$155.1 million. Of this amount, \$78.1 million was denominated in Euros. The remainder, or \$77.0 million, was primarily denominated in U.S. Dollars. Short-term debt

was mainly comprised of our fourth installment of \$28.0 million due March 30, 2005 under our 6.82% senior notes discussed under the heading "Liquidity and Capital Resources" in Item 2 of this Report. To the extent U.S. Dollar and Euro interest rates fluctuate either up or down, the return on the cash investments will also fluctuate. To the extent such Euro cash investments remain outstanding, we will be subject to the risks of future foreign exchange fluctuations and the impact on the translation of these cash investments into U.S. Dollars.

Table of Contents

Interest Rates

Our interest income is sensitive to changes in the general level of short-term interest rates primarily in the United States and Europe. In this regard, changes in the U.S. Dollar and Euro currency rates affect the interest earned on our cash equivalents, short-term investments, and long-term investments. Our interest expense is generated primarily from fixed rate debt. The \$56.0 million 6.82% senior notes outstanding at June 30, 2004 mature evenly in installments of \$28.0 million per year. The two remaining installments are due March 30, 2005 and 2006.

Foreign Currency Exposure

We conduct business throughout the world. During the six months ended June 30, 2004, we derived approximately 55% of our revenues and approximately 40% of our operating income from foreign operations. Economic conditions in countries where we conduct business and changing foreign currency exchange rates affect our financial position and results of operations. We are exposed to changes in foreign exchange rates in Europe, Latin America, and Asia. The Euro and Argentine Peso present our most significant foreign currency exposure risk. Changes in foreign currency exchange rates, especially the strengthening of the U.S. Dollar, may have an adverse effect on our financial position and results of operations as they are expressed in U.S. Dollars. Our manufacturing and administrative operations for Latin America are located in Argentina. A significant part of our Latin American revenues are denominated in U.S. Dollars. Net foreign exchange loss from U.S. Dollar/Euro and U.S. Dollar/Argentine Peso transactions were \$0.2 million for the six-month period ended June 30, 2004.

Management monitors foreign currency exposures and may in the ordinary course of business enter into foreign currency forward contracts or options contracts related to specific foreign currency transactions or anticipated cash flows. These contracts generally cover periods of nine months or less and are not material. For the six months ended June 30, 2004, foreign currency contracts had an approximately neutral impact on our statement of operations. We do not hedge the translation of financial statements of consolidated subsidiaries that maintain their local books and records in foreign currencies.

Risk Factors

Biotechnology and especially the development of products for the health care market are areas of intense competition and high risk. While we believe that our business is unique in its history and areas of focus, the risk factors described below or other risks not known to us now or that we currently believe to be immaterial may have a material and adverse effect on our business, financial condition, results of operations, or the price of our common stock.

If we fail to develop products for the health care and bioproducts markets, we may not achieve a return on our research and development expenditures or realize product revenues from these markets.

A key element of our business strategy is to utilize our technologies for the development and delivery of new products to the health care market and new sectors of the bioproducts market. We intend to continue to invest heavily in research and development to develop products for these markets. The successful development of these products, especially those in the health care market, is highly uncertain and is dependent on numerous factors, many of which are beyond our control, and may include the following:

The product may be ineffective or have undesirable side effects in preliminary and commercial testing or, specifically in the health care area, in preclinical and clinical trials;

The product may fail to receive necessary governmental and regulatory approvals, or such regulatory approvals may be delayed significantly;

The product may not be economically viable because of manufacturing costs or other factors;

The product may not gain acceptance in the marketplace; or

Table of Contents

The proprietary rights of others or competing products or technologies for the same application may preclude us from commercializing the product.

Due to these factors we may never achieve a return on our research and development expenditures or realize product revenues from the health care and new bioproducts markets that we are targeting.

If we fail to enter into strategic alliances with partners in our target markets or fail to independently raise additional capital, we will not have the resources necessary to capitalize on all of the market opportunities available to us.

We do not currently possess the resources necessary to independently develop and commercialize products for all of the market opportunities that may result from our technologies. We intend to form strategic alliances with industry leaders in our target markets to gain access to funding for research and development, expertise in areas we lack and distribution channels. We may fail to enter into the necessary strategic alliances or fail to commercialize the products anticipated from the alliances. Our alliances could be harmed if:

We fail to meet our agreed upon research and development objectives;

We disagree with our strategic partners over material terms of the alliances, such as intellectual property or manufacturing rights; or

Our strategic partners become competitors or enter into agreements with our competitors.

New strategic alliances that we enter into, if any, may conflict with the business objectives of our current strategic partners and negatively impact existing relationships. In addition, to capitalize on the market opportunities we have identified, we may need to seek additional capital, either through private or public offerings of debt or equity securities. Due to market and other conditions beyond our control, we may not be able to raise additional capital on acceptable terms or conditions, if at all.

If the demand for protein degrading enzymes decreases or if major customers reduce or terminate business with us, our revenues could significantly decline.

Our largest selling family of products, protein degrading enzymes, or proteases, accounted for approximately 48% of our 2003 product revenues. If the demand for proteases decreases or alternative proteases render our products noncompetitive, our revenues could significantly decline.

In addition, our five largest customers collectively accounted for approximately 53% of our 2003 product revenues, with our largest customer, The Procter & Gamble Company, accounting for more than 35% of such revenues. Our five largest customers in 2003 were Broin Group; Cargill, Incorporated; Danisco Animal Nutrition - the feed ingredients business unit of Danisco A/S; The Procter & Gamble Company; and Reckitt Benckiser, plc. Any one of these customers may reduce their level of business with us. Should any of our largest customers decide to reduce or terminate business with us, our revenues and profitability could decline significantly.

We have arrangements of various durations with our major customers and are routinely involved in discussions regarding the status of these relationships. These discussions may lead to extensions or new commercial arrangements, or may be unsuccessful. Our customer relationships involve uncertainty by virtue of economic conditions, customer needs, competitive pressures, our production capabilities and other factors. Consequently, we expect that our customer base will continue to change over time as will the nature of our relationships with individual customers, including major customers.

We intend to acquire businesses, technologies and products; however, we may fail to realize the anticipated benefits of such acquisitions and we may incur costs that could significantly reduce our profitability.

In the future, we may acquire other businesses, technologies and products that we believe are a strategic fit with our business. If we undertake any transaction of this sort, we may not be able to successfully integrate any businesses, products, technologies or personnel that we might acquire without a significant expenditure of operating, financial and management resources, if at all. Further, we may fail to realize the anticipated benefits of any acquisition. Future acquisitions could dilute

Table of Contents

our stockholders' interest in us and could cause us to incur substantial debt, expose us to contingent liabilities and could negatively impact our profitability.

If we are unable to secure or maintain adequate intellectual property protection or become involved in an intellectual property dispute, it could significantly harm our financial results and ability to compete.

The patent positions of biotechnology companies, including our patent positions, can be highly uncertain and involve complex legal and factual questions, and, therefore, enforceability is uncertain. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that we protect our technologies with valid and enforceable patents or as trade secrets. We rely in part on trade secret protection for our confidential and proprietary information by entering into confidentiality agreements and non-disclosure policies with our employees and consultants. Nonetheless, confidential and proprietary information may be disclosed, and others may independently develop substantially equivalent information and techniques or otherwise gain access to our trade secrets.

We file patent applications in the United States and in foreign countries as part of our strategy to protect our proprietary products and technologies. The loss of significant patents or the failure of patents to issue from pending patent applications that we consider significant could impair our operations. In addition, third parties could successfully challenge, invalidate or circumvent our issued patents or patents licensed to us so that our patent rights would not create an effective competitive barrier. Further, we may not obtain the patents or licenses to technologies that we will need to develop products for our target markets. The laws of some foreign countries may also not protect our intellectual property rights to the same extent as United States law.

Extensive litigation regarding patents and other intellectual property rights is common in the biotechnology industry. In the ordinary course of business, we periodically receive notices of potential infringement of patents held by others and patent applications that may mature to patents held by others. The impact of such claims of potential infringement, as may from time to time become known to us, are difficult to assess. In the event of an intellectual property dispute, we may become involved in litigation. Intellectual property litigation can be expensive and may divert management's time and resources away from our operations. The outcome of any such litigation is inherently uncertain. Even if we are successful, the litigation can be costly in terms of dollars spent and diversion of management time.

If a third party successfully claims an intellectual property right to technology we use, it may force us to discontinue an important product or product line, alter our products and processes, pay license fees, pay damages for past infringement or cease certain activities. Under these circumstances, we may attempt to obtain a license to this intellectual property; however, we may not be able to do so on commercially reasonable terms, or at all. In addition, regardless of the validity of such a claim, its mere existence may affect the willingness of one or more customers to use or continue to use our products and thereby materially impair our business.

Those companies with which we have entered or may enter into strategic alliances encounter similar risks and uncertainties with respect to their intellectual property. To the extent that any such alliance companies suffer a loss or impairment of their respective technologies, we may suffer a corresponding loss or impairment that may materially and adversely affect our investments.

Also, our patent portfolio includes patents that are nearing the end of their period of protection. While we do not expect to experience a material adverse effect related to patent expirations in the near term, the expiration of patents may submit us to new competition and price pressures that may lead to a significant loss of product revenue.

Foreign currency fluctuations and economic and political conditions in foreign countries could cause our revenues and profits to decline.

In 2003, we derived approximately 55% of our product revenues from our foreign operations. Our foreign operations generate sales and incur expenses in local currency. As a result, we are exposed to market risk related to unpredictable interest rates and foreign currency exchange rate fluctuations. We recognize foreign currency gains or losses arising from our operations in the period incurred. As a result, currency fluctuations between the U.S. Dollar and the currencies in which we do business could cause our revenues and profits to decline.

Table of Contents

Product revenues denominated in Euros accounted for approximately 37% of our total product revenues in 2003, and the fluctuations in the currency exchange rate against the U.S. Dollar can have a significant impact on our reported product revenues.

We expect to continue to operate in foreign countries and that our international sales will continue to account for a significant percentage of our revenues. As such, we are subject to certain risks arising from our international business operations that could be costly in terms of dollars spent, the diversion of management's time, and revenues and profits, including:

Difficulties and costs associated with staffing and managing foreign operations;

Unexpected changes in regulatory requirements;

Difficulties of compliance with a wide variety of foreign laws and regulations;

Changes in our international distribution network and direct sales forces;

Political trade restrictions and exchange controls;

Political, social, or economic unrest including armed conflict and acts of terrorism;

Labor disputes including work stoppages, strikes and embargoes;

Inadequate and unreliable services and infrastructure;

Import or export licensing or permit requirements; and

Greater risk on credit terms and long accounts receivable collection cycles in some foreign countries.

If the ownership of our common stock continues to be highly concentrated, it may prevent other stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline.

After our initial public offering and continuing to the present, Eastman Chemical Company and Danisco A/S and their affiliates, which we refer to as our majority stockholders, each own in excess of 40% of our outstanding common stock. Moreover, pursuant to a Stockholder Agreement, as amended, among Eastman, Danisco and us, each of our majority stockholders also has the right to nominate three of our ten directors. The majority stockholders will therefore have the ability, in the event they act together, to control fundamental corporate transactions requiring stockholder approval, including the election of our directors, the approval of merger transactions involving us, and the sale of all or substantially all of our assets or other business combination transactions. The concentration of ownership of our common stock may have the effect of either delaying or preventing a change to our control favored by our other stockholders or accelerating or approving a change to our control opposed by our other stockholders. In addition, the majority stockholders' control over our management could create conflicts of interest between the majority stockholders and us with respect to the allocation of corporate opportunities and between the majority stockholders and other stockholders.

If stockholders sell large numbers of shares of our common stock, our stock price could decline.

The market price of our common stock could decline as a result of sales of our stock into the public market or the perception that these sales could occur. Our two majority stockholders, for example, hold more than 80% of our

common stock, and all of these shares are subject to registration rights. In addition, we have a significant number of stock options outstanding with our officers, directors and employees pursuant to our 2002 Omnibus Incentive Plan, approved by our stockholders in May 2002, and its predecessor plan.

Our stock price has been, and may continue to be, particularly volatile.

The stock market from time to time, has experienced significant price and volume fluctuations that are unrelated to the operating performance of companies. The market prices for securities of biotechnology companies, including ours,

Table of Contents

have been highly volatile in the period since our initial public offering in July 2000 and may continue to be highly volatile in the future. Our stock may be affected by this type of market volatility, as well as by our own performance. The following factors, among other risk factors, may have a significant effect on the market price of our common stock:

Developments in our relationships with current or future strategic partners;

Conditions or trends in the biotechnology industry;

Announcements of technological innovations or new products by us or our competitors;

Announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

Developments in patent or other intellectual proprietary rights or announcements relating to these matters;

Investor concern regarding the public acceptance of the safety of biotechnology products or announcements relating to these matters;

Litigation or governmental proceedings or announcements relating to these matters;

Economic and other external factors or other disaster or crisis;

Future royalties from product sales, if any, by our licensees;

Sales of our common stock or other securities in the open market; and

Period-to-period fluctuations in our operating results.

We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline thereby causing investor losses.

A large portion of our expenses, including expenses for facilities, equipment and personnel, are relatively fixed. Accordingly, if product revenue declines or does not grow as we anticipate or non-product revenue declines due to the expiration or termination of strategic alliance agreements or the failure to obtain new agreements or grants, we may not be able to correspondingly reduce our operating expenses in any particular quarter. Our quarterly revenue and operating results have fluctuated in the past and are likely to do so in the future. If our operating results in some quarters fail to meet the expectations of stock market analysts and investors, our stock price would likely decline. Some of the factors that could cause our revenue and operating results to fluctuate include:

The ability and willingness of strategic partners to commercialize products derived from our technology or containing our products on expected timelines;

Our ability to successfully commercialize products developed independently and the rate of adoption of such products;

Fluctuations in consumer demand for products containing our technologies or products, such as back to school sales of blue jeans and other denim products, resulting in an increase in the use of textile processing enzymes, and fluctuations in laundry detergent use due to promotional campaigns run by consumer products companies; and

Fluctuations in geographic conditions including currency and other economic conditions such as economic crises in Latin America or Asia and increased energy and related transportation costs.

We also have incurred significant infrequently occurring charges within given quarters, such as those incurred in conjunction with restructuring activities and recognized investment income/expense from available-for-sale marketable securities.

Table of Contents

Concerns about genetically engineered products could result in our inability to commercialize products.

We produce a significant amount of our products from genetically modified microorganisms. We cannot predict public attitudes and acceptance of existing or future products made from genetically modified microorganisms. As a result, if we are not able to overcome the ethical, legal and social concerns relating to safety and environmental hazards of genetic engineering, the general public may not accept our products and this may prevent us from commercializing products dependent on our technologies or inventions. In addition, public attitudes may influence laws and regulations governing the ownership or use of genetic material, which could result in greater government regulation of genetic research and bioengineered products.

If we are subject to a costly product liability damage claim or award, our profits could decline.

We may be held liable if any product we develop, or any product that a third party makes with the use or incorporation of any of our products, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Our current product liability insurance may not cover our potential liabilities. Inability to obtain sufficient insurance coverage in the future at an acceptable cost or otherwise to protect against potential liability claims could prevent or inhibit the commercialization of products developed by us or our strategic partners. If a third party sues us for any injury caused by our products, our liability could exceed our insurance coverage amounts and total assets and our profits could decline.

If we are subject to costly environmental liability due to the use of hazardous materials in our business, our profits could decline.

Our research and development processes involve the controlled use of hazardous materials, including chemical, radioactive and biological materials. Our operations also generate potentially hazardous waste. We cannot eliminate entirely the risk of contamination or the discharge of hazardous materials and any resultant injury from these materials. Federal, state, local and foreign laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. Third parties may sue us for any injury or contamination resulting from our use or the third party's use of these materials. Any accident could partially or completely shut down our research and manufacturing facilities and operations. In addition, if we are required to comply with any additional applicable environmental laws and regulations, we may incur additional costs, and any such current or future environmental regulations may impair our research, development or production efforts.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The information presented in Item 2 of Part I of this Report on Form 10-Q under the heading "Market Risk" is hereby incorporated by reference.

Item 4. Controls and Procedures

Disclosure Controls and Internal Controls

Disclosure Controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (Exchange Act), such as this Report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure Controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief

Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Internal Controls are procedures which are designed with the objective of providing reasonable assurance that (1) our transactions are properly authorized; (2) our assets are safeguarded against unauthorized or improper use; and (3) our transactions are properly recorded and reported, all to permit the preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America. Accordingly, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Report, we carried out an evaluation, under the supervision and with the participation of our management, including Jean-Jacques Bienaimé, our Chairman, Chief Executive Officer and President, and Raymond J. Land, our Senior Vice President and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, Mr. Bienaimé and Mr. Land concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Report.

Changes in Internal Controls Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the second quarter of 2004 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On or about July 16, 2004, three former employees of the Company in Rochester, New York commenced a lawsuit in the United States District Court for the Western District of New York in which they alleged that the Company had discriminatorily discharged each of them in violation of the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, and the New York Human Rights Law. In the lawsuit, the plaintiffs are seeking an award from the court that includes compensation for the value of lost back pay and benefits, front pay, compensatory damages, punitive damages and attorneys' fees. The Company believes these claims are without merit and intends to defend the claims alleged in the lawsuit.

Item 2. Change in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

The information presented in Item 2 of Part I of this Report on Form 10-Q under the heading "Liquidity and Capital Resources" is hereby incorporated by reference. The Company's Registration Statement on Form S-1 (Registration No. 333-36452) was effective as of July 27, 2000.

Item 3. Defaults Upon Senior Securities

None

Table of Contents**Item 4. Submission of Matters to a Vote of Security Holders**

The Annual Meeting of Stockholders of the Company was held on May 27, 2004. At that meeting, the stockholders elected directors and ratified the selection of PricewaterhouseCoopers LLP as independent accountants for the fiscal year ended December 31, 2004. The total votes at the meeting were as follows:

- (i) To elect directors to serve a three-year term.

Nominee	Votes	
	For	Withheld
Theresa K. Lee	58,596,432	275,510
Robert H. Mayer	58,385,036	486,906
Jorgen Rosenlund	58,596,357	275,585

There were no broker non-votes.

Directors whose term in office continued after the meeting:

Term expiring in 2005: Soren Bjerre-Nielsen, Joseph A. Mollica, Gregory O. Nelson, James P. Rogers

Term expiring in 2006: Jean-Jacques Bienaimé, Bruce C. Cozadd, Norbert G. Riedel

- (ii) To ratify the selection of PricewaterhouseCoopers LLP as independent accountants for the fiscal year ending December 31, 2004.

Votes		
For	Against	Abstain
58,501,166	367,112	3,664

There were no broker non-votes.

Item 5. Other Information

On June 15, 2004, the Company appointed Margaret (Peg) Horn as its new Senior Vice President, General Counsel and Secretary to the Board of Directors. Ms. Horn succeeded Stuart Melton who stepped down from his positions as General Counsel and Secretary immediately prior to Ms. Horn's appointment and will retire effective January 1, 2005.

On July 8, 2004, the Company amended its employment agreement with Jean-Jacques Bienaimé, our Chairman, Chief Executive Officer and President. The employment agreement provides for an annual salary of \$546,000 and provides that Mr. Bienaimé's salary may be increased from time to time by action of our board of directors or by our management development and compensation committee and that these increases constitute amendments to Mr. Bienaimé's employment agreement. Mr. Bienaimé is entitled to participate in all insurance, pension, retirement, deferred compensation, stock and stock option, stock purchase or similar compensation and benefit plans and programs of the Company. Mr. Bienaimé is also entitled to cash payments to cover the costs of an annual physical not covered by health insurance benefits and the costs of financial planning and income tax preparation services. In addition, the Company has agreed to maintain for his benefit a fully-paid whole life insurance policy with a stated death benefit of \$500,000. In the event that the Company terminates Mr. Bienaimé's employment without cause or in

the event that Mr. Bienaimé resigns due to a constructive removal, a forced

Table of Contents

relocation, a decrease in salary or benefits or the Company's breach of the agreement, he will receive severance in the form of continued compensation for 24 months at his then current annual salary rate, a cash bonus under the Company's variable pay plan, continuation of company-paid benefits for 24 months, and customary executive outplacement services limited to \$18,000.

Further, in the event the Company terminates Mr. Bienaimé's employment without cause following a change in our ownership or control in which more than 50 percent of our outstanding shares of common stock are acquired by an unaffiliated third party, in lieu of the foregoing severance, he will receive an enhanced severance (Enhanced Severance) in the form of continued cash compensation for 30 months equal to the sum of his then current annual salary rate plus bonus at 100 percent of target, continuation of company-paid benefits for 30 months, the monetary equivalent of the crediting of an additional five years of service to the pension plan and immediate eligibility for retiree medical plan for purposes of determining benefits payable under these plans, a cash payment of \$18,000 for customary executive outplacement services, a cash payment for the cost of annual physical examinations in the year of termination and for two additional years thereafter which are not covered by health insurance benefits, a fully-paid whole life insurance policy with a stated death benefit of \$500,000, a cash payment intended to cover the out of pocket expenses incurred by Mr. Bienaimé annually for state and federal income tax return preparation for the year of termination and two additional years, the Company's annual contribution to his 401K Plan account for the year in which termination occurs, and a full year's credit towards his benefits under the Company's pension plan. In addition to the Enhanced Severance, Mr. Bienaimé would be eligible for a discretionary bonus, if granted, in connection with a change in control and would be entitled to receive an additional payment to reimburse Mr. Bienaimé for any excise tax otherwise payable by him as a result of the Enhanced Severance. Also, certain benefits included in the agreement are to be supplemented by the Company to compensate Mr. Bienaimé for taxes payable on such benefits. In either severance event, we would compensate Mr. Bienaimé for the applicable 24 or 30 month-period, respectively, if his employment is terminated due to a permanent disability.

In July, the Company also entered into employment agreements with each of the executive officers. These employment agreements each have a one year term with automatic one year renewals unless otherwise agreed, with bonus compensation to be determined by our board of directors or our management development and compensation committee. Each executive officer's salary may be increased from time to time by action of our management development and compensation committee, and these increases constitute amendments to his or her employment agreement. Each executive officer is entitled to participate in all of our insurance, pension, retirement, deferred compensation, stock and stock option, stock purchase or similar compensation and benefit plans and programs of the Company. In the event that the Company terminates a named executive officer's employment without cause, or in the event that the executive officer resigns due to a constructive removal, a forced relocation, a decrease in salary or benefits or the Company's breach of the agreement, he or she will receive severance in the form of continued compensation for 18 months at his or her then current annual salary rate, a cash bonus under the Company's variable pay plan, continuation of company-paid benefits for 18 months, and outplacement services of \$18,000. As with Mr. Bienaimé, each executive officer is also eligible to receive the Enhanced Severance termination compensation for 30 months in lieu of the foregoing severance, except that the whole life insurance policy stated death benefit shall be \$300,000. The Company will continue to compensate each of these individuals for the applicable 18 or 30 month-period, respectively, if that person's employment is terminated due to a permanent disability. In addition, for the two executive officers currently receiving declining housing supplements, at levels which were frozen in 2003, these officers would continue to receive such payments for the applicable 18 or 30-month period described above.

Item 6. Exhibits and Reports on Form 8-K

a. Exhibits

(10) Material Contracts

- +10.1 Amended and Restated Research Agreement dated June 14, 2004 between Dow Corning Corporation and the Company
- #10.2 Employment and Separation Agreement dated May 1, 2004 between the Company and Stuart Melton
- #10.3 Employment Agreement dated July 8, 2004 between the Company and Jean-Jacques Bienaimé

Table of Contents

#10.4	Form of Employment Agreement between the Company and its executive officers
10.5	Rental Agreement originally dated April 29, 1966 between the City of Hanko and the Company's ultimate predecessor-in-interest, Suomen Sokeri Osakeyhtio [Ground Lease for Hanko, Finland]
(31)	<u>Rule 13a-14(a)/15d-14(a) Certifications</u>
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
(32)	<u>Section 1350 Certifications</u>
32.1	Section 1350 Certifications of the Chief Executive Officer and the Chief Financial Officer

+	Confidential treatment requested as to certain information which has been omitted from the agreement and which has been separately filed with the Securities and Exchange Commission pursuant to an application for such treatment.
---	---

#	Management contract or compensatory plan.
---	---

b. Reports on Form 8-K

On April 29, 2004 the Company furnished a Current Report on Form 8-K reporting its press release concerning financial results for the first quarter of 2004 under Items 7 and 12. The report included condensed financial statements and other financial information.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENENCOR INTERNATIONAL, INC.

August 6, 2004

By:/s/ Raymond J. Land

Date

Raymond J. Land
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)

August 6, 2004

By:/s/ Darryl L. Canfield

Date

Darryl L. Canfield
Vice President and Corporate Controller
(Chief Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
+10.1	Amended and Restated Research Agreement dated June 14, 2004 between Dow Corning Corporation and the Company.
#10.2	Employment and Separation Agreement dated May 1, 2004 between the Company and Stuart Melton
#10.3	Employment Agreement dated July 8, 2004 between the Company and Jean-Jacques Bienaimé
#10.4	Form of Employment Agreement between the Company and its executive officers
10.5	Rental Agreement originally dated April 29, 1966 between the City of Hanko and the Company's ultimate predecessor-in-interest, Suomen Sokeri Osakeyhtiö [Ground Lease for Hanko, Finland]
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certifications of the Chief Executive Officer and the Chief Financial Officer

+ Confidential treatment requested as to certain information which has been omitted from the agreement and which has been separately filed with the Securities and Exchange Commission pursuant to an application for such treatment.

Management contract or compensatory plan